# H7HLAII DNA Influenza Vaccine

> **NCT06046092** · PHASE1 · UNKNOWN · sponsor: **Oslo University Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Influenza A
- Pandemic Influenza

## Interventions

- **BIOLOGICAL:** H7HLAII

## Key facts

- **NCT ID:** NCT06046092
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-15
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06046092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06046092, "H7HLAII DNA Influenza Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06046092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*